In this study we have analyzed the consequences, on several neuroblastoma cell lines, of combined treatments with (R)-roscovitine (CYC202, Seliciclib), a CDK inhibitory drug, and nutlin-3, a p53 activating drug. Both compounds were found to synergize, causing significant levels of apoptosis in cultured cells when combined at sub-lethal concentrations.
INTRODUCTION
Nutlin-3 is a cis-imidazoline compound that has recently been described as a potent and selective antagonist of MDM2 binding to the p53 protein. Nutlin-3 is thus a promising new molecular scaffold able to unleash the p53 tumor suppressing power in cancer cells [1] .
MDM2, HDM2 in human, is encoded by a gene under the positive transcriptional control of p53 [2] . In contrast, HDM2 is a negative regulator of p53 function as it promotes p53 export from the nucleus and its subsequent ubiquitin/proteasome mediated degradation [3] . This negative feed-back loop between the two proteins is targeted by nutlin-3 which, consequently, stabilizes p53.
Cyclin-dependent kinase (CDKs) inhibitory drugs are also being extensively studied as promising agents for cancer therapy [4, 5] . Among the first inhibitors, (R)-roscovitine (CYC202, Seliciclib) has reached phase II clinical trials against breast cancer, various B-cell malignancies and non small cell lung cancer [6] [7] [8] . Roscovitine has proven to be an effective inducer of apoptosis in a large diversity of human cells including those from breast cancers [9] , chronic lymphocytic leukemia [10] or neuroblastoma [11] .
Roscovitine has been shown to be active in combination with various treatments such as irradiation therapy of breast cancer [12] or farnesyltransferase inhibitors in several cancer cell lines [13] . As a matter of fact, the clinical trials of (R)-Roscovitine are conducted as a combination with standard chemotherapy [4, 7, 14] . These antecedents prompted us to explore whether nutlin-3 and (R)-roscovitine displayed some pharmacological synergism in several cell lines derived from human neuroblastoma.
SH-SY5Y is a cell line derived from an abdominal metastasis of a human neuroblastoma in which we have been studying apoptotic processes induced, for instance, by roscovitine [11] . In many neuroblastoma cells, like SH-SY5Y, p53 protein is present and capable to trigger the canonical p53-mediated transcriptional responses and apoptosis [15] .
We found that (R)-roscovitine and nutlin-3 synergize in inducing apoptosis in several cell lines derived from neuroblastoma. In SH-SY5Y cells, Bcl-XL overexpression failed to prevent Ribas et al.
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We conclude that sublethal concentrations of (R)-roscovitine enhance the apoptotic response of neuroblastoma cells triggered by nutlin-3. 
MATERIAL AND METHODS

Chemical reagents
Cell line culture and treatment
SH-SY5Y, IMR-5 and IMR-32 cells were grown in DMEM medium from Cambrex (Emerainville, France) supplemented with 2 mM L-glutamine from Eurobio (Courtaboeuf, France) and a 10% volume of fetal calf serum from Invitrogen (Cergy Pontoise, France). Cell cultures were maintained in a 95% air, 5% CO 2 , water saturated atmosphere at 37°C.
Culture dishes and other plastic disposable tools were supplied by Corning (Corning, NY, USA). SH-SY5Y cell clones transfected with the pcDNA3/Bcl-XL and the pcDNA3 empty vector were obtained and cultivated as reported previously [11, 16] . (R)-roscovitine and nutlin-3 stock solutions were prepared in DMSO at a 20 mM concentration. From these stock solutions, drugs were adjusted in the culture media at the final concentrations reported in the 
Determination of cell death, cell viability and effector caspase activity
The MTS method allows to measure cell viability while the LDH release determination provides an estimate of cell death level. Both procedures can be carried out in the culture multiwell plates. They were performed according to providers' instructions and as previously multiwell plates was performed as previously standardized [11, 16] .
Protein extraction and Western blotting
Cells extracts for Western blotting analysis were prepared as follows. Cells were first washed with PBS (Phosphate Buffered Saline) and lysed by sonication in a buffer containing 1% SDS, 50 mM Tris-HCl (pH 6.8), 1 mM EDTA and a cocktail of protease inhibitors (10 µg/ml Aprotinin, 10 µg/ml Leupeptin, 100 µM Benzamidine). Following room temperature centrifugation at 12000 g for 15 min, the protein extract ( 
RESULTS (R)-roscovitine and nutlin-3 synergize at inducing apoptosis in neuroblastoma cells
The first step to evaluate a putative synergy between (R)-roscovitine and nutlin-3
was to determine the range of concentrations causing SH-SY5Y cell death for each compound, separately. The MTS reduction assay was used to quantify cell viability. This allowed us to define a lethal (37.5 -50 µM) and a sublethal (10 µM) concentration for (R)-roscovitine, and a lethal (5 -10 µM) and almost sublethal (2.5 µM) concentration for nutlin-3, following 48 hr of treatment (Fig. 1A) . We next tested the combined addition of (R)-roscovitine (10 µM) and nutlin-3 (2.5 µM). A reduction in cell viability, far greater than that caused by each drug used individually at the sublethal concentration, was observed (Fig.   1A ). It is known MTS reduction can be caused by cellular events different from cell death. To circumvent this uncertainty, we have systematically validated the MTS results by using the LDH release method [11] . As shown in Fig. 1B , cell death quantification by the LDH release procedure yielded values consistent with those provided by the MTS assay. In conclusion, a pharmacological synergism existed in SH-SY5Y cells.
We followed a similar approach In IMR-5 and IMR-32, two additional cell lines derived from human neuroblastoma. (R)-roscovitine and nutlin-3 were tested and cell death was found to occur in the same range of concentrations previously determined for SH-SHY5Y cells. The pharmacological synergism was also tested and found to exist in both cell lines (Table 1) .
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The MTS reduction and LDH release procedures are quite appropriate to quantify cell viability and cell death in culture plates. However, they do not provide any information about the ongoing type of cell death. In order to assess the mechanism of cell death induced by the combination of (R)-roscovitine (10 µM) and nutlin-3 (2.5 µM), two complementary approaches were used. First, bisBenzimide staining and fluorescence microscopy allowed the unequivocal identification of apoptotic nuclei (Fig. 2) . Second, the determination of DEVDase activity, by quantification of the cleavage of the fluorogenic substrate AcDEVDafc, provided an estimation of the effector caspase 3 and 7 activity (Fig. 3 ). An increase of DEVDase activity is considered as an early biochemical marker of apoptosis. A marked increase in DEVDase activity was observed after 12 hr of exposure to (R)-roscovitine (10 µM) plus Nutlin-3 (2.5 µM). In these DEVDase experiments, cell death was confirmed at 48 hr using the Trypan blue staining procedure. The cell death ratios were 5.56 ± 1.25 % for (R)-roscovitine (10 µM), 9.67 ± 1.58% for nutlin-3, and 46.35 ± 3.22% for the combined treatment in SH-SY5Y cells. These values of cell death were consistent with those obtained with the LDH release method (Fig. 1B) , thus providing full biological significance to the DEVDase activity experiments. Similar results were observed in IMR-5 and IMR-32 cell lines subjected to the combined treatment (Fig. 3) . After 12 hr of exposure to (R)-roscovitine (12.5 µM) plus Nutlin-3 (2.5 µM) a synergistic activation of effector caspases was found. In conclusion, not only was the cell death process identified as apoptotic but further support of the pharmacological synergism was provided.
(R)-roscovitine acts by sensitizing SH-SY5Y cells to nutlin-3 pro-apoptotic effects
In addition to the 48 hr end point for the cell death and cell viability determinations (Fig. 1) , we had also performed measurements after 24 hr of treatment. Taken together, all these results allowed us to compare the time-course leading to cell death in SH-SY5Y cells exposed to these treatments (Fig. 4) . As expected from previous data [11], a lethal concentration of (R)-roscovitine killed most of SH-SY5Y cells at 24 hr. On the contrary, a
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This was in agreement with the reported 48 hr optimal delay required to detect Nutlin-3 induced apoptosis in other cell types [1] . Interestingly, the time-course of cell death induction by the combined treatment with (R)-roscovitine (10 µM) plus Nutlin-3 (2.5 µM) was parallel to that displayed by deadly doses of Nutlin-3 (Fig. 4) . This fact suggests that the apoptotic mechanisms triggered by the combined therapy are closer to those derived from Nutlin-3 than to those due to (R)-roscovitine.
Nutlin-3 acts as a p53 activator and p53-induced apoptosis is known to partially occur through mitochondrial outer membrane permeability transition [17, 18] . Bcl-XL is a protein of the Bcl-2 family known to exceed Bcl-2 in its ability to neutralize mitochondrialmediated apoptosis. For instance Bcl-XL overexpression in SH-SY5Y cells, but not Bcl-2 overexpression, is able to counteract staurosporine-induced apoptosis [16] . We therefore investigated the effect of Bcl-XL overexpression on the apoptotic process triggered by (R)-roscovitine, nutlin-3 and the combined treatment. SH-SY5Y cells overexpressing Bcl-XL and empty vector transfected controls were used [16] . As a functional control, we first verified that these Bcl-XL overexpressing cells were resistant to staurosporine-induced apoptosis (Fig. 5A) . We further confirmed that, as previously reported [11], neither Bcl-2 nor Bcl-XL overexpression were able to protect SH-SY5Y cells from apoptosis triggered by racemic roscovitine or (R)-roscovitine (Fig. 5A ).
We next tested the effect of Bcl-XL overexpression on nutlin-3 induced apoptosis.
Bcl-XL overexpression was found to protect SH-SY5Y cells from the apoptotic consequences of a 48 hr treatment with a lethal concentration of nutlin-3 (Fig. 5B) . This was not an unexpected finding given the mitochondrial mechanisms of apoptosis triggered by the p53 protein. When 10 µM (R)-roscovitine + 2.5 µM nutlin-3 were tested on the pcDNA3/Bcl-XL transfected cells an increase of cell viability was also found (Fig. 5B) . The combined treatment and 10 µM nutlin-3 alone caused a similar level of cell death. Facing these apoptotic stimuli (combination or nutlin-3 alone), the extent of cell protection by Bcl-XL overexpression was also remarkably similar (Fig. 5B) . This result provides additional and relevant clues concerning the nature of the synergy between (R)-roscovitine and nutlin-3.
The apoptotic pathway underlying the combined treatment behaves identically to the pathway engaged by lethal concentrations of nutlin-3 alone. Therefore we propose that (R)-roscovitine acts by sensitizing SH-SY5Y cells to the nutlin-3 action on p53.
To further support this conclusion, we explored how these drug treatments were impinging on p53 protein and its transcriptional function. We analyzed the cell content of p53
and two of its transcriptional targets, HDM2 and p21
Cip1
, by SDS-PAGE followed by Western blotting (Fig. 6) . A 24 hr treatment with (R)-roscovitine (10 µM) was sufficient to induce the stabilization of p53 protein but not apoptosis. In coherence with its reported mode of action, nutlin-3 stabilized p53 and increased HDM2 and p21 Cip1 protein content in a dose-dependent manner. Interestingly, the combination of 10 µM (R)-roscovitine + 2.5 µM nutlin-3 led to an increased expression of p53, HDM2 and p21 Cip1 similar to that observed with 10 µM nutlin-3
alone. This result provides a clue for further studies on the molecular mechanisms causing the synergy between (R)-roscovitine and nutlin-3.
DISCUSSION
In this report we have shown (R)-roscovitine synergizes with nutlin-3 at inducing apoptosis in SH-SY5Y, IMR-5 and IMR-32 cell lines derived from human neuroblastoma. In SH-SY5Y cells, Bcl-XL overexpression experiments and protein analysis of p53 stability and transcriptional functions allow us to propose that (R)-roscovitine merely acts by increasing the cellular responses to nutlin-3, namely activation of p53, its downstream targets and apoptosis induction. Our results are consistent with the reported mode of action of nutlin-3, i.e. the inhibition of the interaction between p53 and HDM-2, leading to a stabilization of p53.
Apoptosis in response to p53 is known to occur by multiple simultaneous mechanisms, mitochondrial and non-mitochondrial, transcriptional and non-transcriptional [17, 18] . Bcl-XL protein is well known by its ability to block mitochondrial mediated apoptosis and, consequently, its overexpression in SH-SY5Y provided a partial protection from nutlin-3/p53 mediated apoptosis.
Our results suggest that the synergism between nutlin-3 and (R)-roscovitine in inducing apoptosis relies on the potentiation of nutlin-3 actions by (R)-roscovitine. What is the molecular mechanism involved in this potentiation? (R)-roscovitine is a CDK-inhibitory drug that has demonstrated to be very selective for CDKs in biochemical assays [19] [20] [21] .
How could the inhibition of one or more CDK contribute to the stability of the p53 protein?
The activation of p53 has been reported in cells challenged with roscovitine and this might be due to a decrease in HDM-2 protein [22] . However, in SH-SY5Y cells exposed to sublethal concentrations of (R)-roscovitine, we have observed a slight increase, rather than a decrease, in HDM-2 level (Fig. 6) . The pharmacological inhibition of CDK9 has proven to promote the nuclear accumulation of p53 without diminishing MDM-2 transcription [23] .
Furthermore, the inhibition of CDK2 has been reported to activate an intra-S-phase checkpopint that leads to an ATM/ATR-dependent phosphorylation and activation of p53
protein [24] . Interestingly, CDK9 and CDK2 are among the most sensitive targets of (R)-roscovitine.
The apoptotic process triggered by either racemic roscovitine [11] or (R)-roscovitine (this report) is insensitive to the overexpression of either Bcl-XL or Bcl-2. In contrast Bcl-XL overexpression protects SH-SY5Y cells from nutlin-3 triggered, p53 mediated apoptosis.
Taken together, these data suggest only a minor, if any, role for p53 in the apoptotic process triggered by roscovitine itself. In other words, the mitochondrial mechanisms activated by p53 to cause apoptosis does not seem to be involved in the apoptotic process induced by CDK inhibitory drugs like (R)-roscovitine, racemic roscovitine or olomoucine alone.
A deficit in p53 function is found in more than 50% of all human cancers. However in many cancer types, a functional p53 system is present. This is the case of human neuroblastoma tumors and cell lines, like SH-SY5Y [15] . Therefore, nutlin-3 constitutes a promising drug for the treatment of this childhood malignancy. The synergism we report here were treated with lethal concentrations of (R)-roscovitine (R) (37.5 µM) and nutlin-3 (N) (5 µM). Cells were also treated with a combination of both drugs (R+N), but at their sublethal concentrations (10 and 2.5 µM, respectively). Cell viability was determined by the MTS reduction assay following 24 hr (black bars) and 48 hr (white bars) treatment. Cell death (%) = 100 -cell viability (%). Mean ± SEM of at least five independent experiments with at least three independent determinations per experiment are shown. 
